The aim of the study was to assess the status of routine immunization status and reasons for drop-outs in five districts in Bihar India. A community based cross sectional rapid survey in five districts in Bihar was undertaken from 11th January to 5th February 2013. Of the 38 districts in Bihar, 5 districts prioritized by the state government for intensive routine immunization support were selected purposively for the rapid assessment. Samples of primary health centres, Health sub centres, villages were chosen for the study using geographic and performance criteria. Twenty households having babies 0 to 36 months old from each village were randomly selected. A total of 7,500 households were taken from the 5 study districts. Apart from household survey, cold chain points where vaccines are stored and vaccination session sites were also assessed for service delivery and community participation. The assessment findings revealed high access resulted in good coverage of the initial vaccination such as BCG and DPT1, while low utilization due to drop out of children from DPT1 to DPT3 (15%) and BCG –measles dropout (27%). The coverage was inequitable, with 12% difference in full immunization among children below poverty line and scheduled caste and tribe children. The reasons for low vaccination coverage were both related to demand and supply side. Lack of awareness on immunization, lack of correct information about the place and time of immunization, illness of the child at the time of immunization session, irregular session timing and fear of adverse effects were found to be the major causes for almost 60% of households. The health staff ascribed it mainly to erratic supply of vaccines and logistics, poor planning, insignificant role of media or past experience of Adverse Effect Following Immunization (AEFI) as major causes. Based on the assessment of cold chain and vaccination session facility and key informant interviews, it was recommended that special emphasis should be given to due list preparation and tracking of beneficiaries using local volunteers, self-help groups and mobilizers especially in hard to reach areas. In addition, to ensure regular vaccine and logistic availability, Microplanning to include disadvantaged communities like Scheduled Caste (SC)/Scheduled Tribe (ST) & Below Poverty Line (BPL) households and intensive monitoring using both internal and external supervisors for regular monitoring of the routine immunization activities

Throughout the years, various classifications have evolved for the diagnosis of vascular anomalies. However, it remains difficult to classify a number of such lesions. Because all hemangiomas were previously considered to involute, if a lesion with imaging and clinical characteristics of hemangioma does not involute, then there is no subclass in which to classify such a lesion, as reported in one of our cases. The recent classification proposed by the International Society for the Study of Vascular Anomalies (ISSVA, 2014) has solved this problem by including non-involuting and partially involuting hemangioma in the classification. We present here five cases of vascular anomalies and discuss their diagnosis in accordance with the ISSVA (2014) classification. A non-involuting lesion should not always be diagnosed as a vascular malformation. A non-involuting lesion can be either a hemangioma or a vascular malformation depending upon its clinicopathologic and imaging characteristics.
Classification ; Diagnosis* ; Head* ; Hemangioma ; Neck* ; Vascular Malformations

Background: Morphological diagnosis of non-Hodgkin lymphoma (NHL) is usually based on lymph node biopsy. Bone marrow biopsy (BMB) is important for staging, and morphology alone can be challenging for subtyping. Immunohistochemistry (IHC) allows a more precise diagnosis and characterization of NHL using monoclonal antibodies. However, there is a need for a minimal panel that can provide maximum information at an affordable cost. Methods: All newly diagnosed cases of B-cell NHL with bone marrow infiltration between 2017 and 2019 were included. BMB was the primary procedure for diagnosing B-cell NHL. Subtyping of lymphomas was performed by immunophenotyping using a panel of monoclonal antibodies on IHC. The primary diagnostic panel of antibodies for B-cell NHL included CD19, CD20, CD79, CD5, CD23, CD10, Kappa, and Lambda. The extended panel of antibodies for further subtyping included CD30, CD45, CD56, Cyclin D1, BCL2, and BCL6. Results: All cases of B-cell NHL were classified into the chronic lymphocytic leukemia (CLL) and non-CLL groups based on morphology and primary IHC panel. In the CLL group, the most significant findings were CD5 expression, CD23 expression, dim CD79 expression, and weak surface immunoglobulin (Ig) positivity. In the non-CLL group, they were CD5 expression, positive or negative CD23 expression, strong CD79 expression, and strong surface Ig expression. An extended panel was used for further subtyping of non-CLL cases, which comprised CD10, Cyclin D1, BCL2, and BCL6. Conclusion We propose a two-tier approach for immunophenotypic analysis of newly diagnosed B-cell NHL cases with a minimum primary panel including CD5, CD23, CD79, Kappa, and Lambda for differentiation into CLLon-CLL group and Kappa and Lambda for clonality assessment. An extended panel may be used wherever required for further subtyping of non-CLL.